Year:
2015 PI Name: Zhang Wensheng PubMed/DOI:
25714973
Protective effect of notoginsenoside R1 on an APP/PS1 mouse model of Alzheimer's disease by up-regulating insulin degrading enzyme and inhibiting Aβ accumulation Therapeutic Agent(s):
Notoginsenoside R1 (NTR1)
Protective effect of notoginsenoside R1 on an APP/PS1 mouse model of Alzheimer's disease by up-regulating insulin degrading enzyme and inhibiting Aβ accumulation
Year:
2016 PI Name: Kwon Jungkee PubMed/DOI:
27286707
6-Shogaol has anti-amyloidogenic activity and ameliorates Alzheimer’s disease via CysLT1R-mediated inhibition of cathepsin B Therapeutic Agent(s):
6-Shogaol has anti-amyloidogenic activity and ameliorates Alzheimer’s disease via CysLT1R-mediated inhibition of cathepsin B
Year:
2016 PI Name: Qin Chuan PubMed/DOI:
27240542
Cyanidin 3-O-β-glucopyranoside activates peroxisome proliferator-activated receptor-γ and alleviates cognitive impairment in the APPswe/PS1ΔE9 mouse model Therapeutic Agent(s):
Cyanidin 3-O-β-glucopyranoside
Cyanidin 3-O-β-glucopyranoside activates peroxisome proliferator-activated receptor-γ and alleviates cognitive impairment in the APPswe/PS1ΔE9 mouse model
Year:
2016 PI Name: Li Yan-Bing PubMed/DOI:
27518086
Fuzhisan ameliorates the memory deficits in aged SAMP8 mice via decreasing Aβ production and tau hyperphosphorylation of the hippocampus Therapeutic Agent(s):
Fuzhisan ameliorates the memory deficits in aged SAMP8 mice via decreasing Aβ production and tau hyperphosphorylation of the hippocampus
Year:
2016 PI Name: Shen Xu PubMed/DOI:
27569389
Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance Therapeutic Agent(s):
Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance
Year:
2016 PI Name: Gasparini Laura PubMed/DOI:
26858121
Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy Therapeutic Agent(s):
Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy
Year:
2016 PI Name: Bao Xinjie PubMed/DOI:
27932977
Human neural stem cell transplantation rescues cognitive defects in APP/PS1 model of Alzheimer's disease by enhancing neuronal connectivity and metabolic activity Therapeutic Agent(s):
HuCNS-SC (Human Neural Stem Cell Population)
Human neural stem cell transplantation rescues cognitive defects in APP/PS1 model of Alzheimer's disease by enhancing neuronal connectivity and metabolic activity
Year:
2017 PI Name: Town Terrence PubMed/DOI:
28512130
Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer’s disease Therapeutic Agent(s):
Octyl Gallate Ferulic Acid
Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer’s disease
Year:
2017 PI Name: Wu Meina PubMed/DOI:
28731445
Colivelin ameliorates impairments in cognitive behaviors and synaptic plasticity in APP/PS1 transgenic mice Therapeutic Agent(s):
Colivelin ameliorates impairments in cognitive behaviors and synaptic plasticity in APP/PS1 transgenic mice
Year:
2017 PI Name: Du Jun-Rong PubMed/DOI:
29163135
Neuroprotective effect of ligustilide through induction of α-secretase processing of both APP and klotho in a mouse model of Alzheimer’s disease Therapeutic Agent(s):
Neuroprotective effect of ligustilide through induction of α-secretase processing of both APP and klotho in a mouse model of Alzheimer’s disease
Year:
2017 PI Name: Hong Yan PubMed/DOI:
28269786
Dietary lycopene supplementation improves cognitive performances in tau transgenic mice expressing P301L mutation via inhibiting oxidative stress and tau hyperphosphorylation Therapeutic Agent(s):
Dietary lycopene supplementation improves cognitive performances in tau transgenic mice expressing P301L mutation via inhibiting oxidative stress and tau hyperphosphorylation
Year:
2017 PI Name: Tan Jun PubMed/DOI:
28617434
LISPRO mitigates β-amyloid and associated pathologies in Alzheimer's mice Therapeutic Agent(s):
LISPRO mitigates β-amyloid and associated pathologies in Alzheimer's mice
Year:
2017 PI Name: Wang Dongmei PubMed/DOI:
27435287
The effects of astilbin on cognitive impairments in a transgenic mouse model of Alzheimer’s disease Therapeutic Agent(s):
The effects of astilbin on cognitive impairments in a transgenic mouse model of Alzheimer’s disease
Year:
2017 PI Name: Cho Jae-Hyeon PubMed/DOI:
28072821
Maysin and its flavonoid derivative from centipedegrass attenuates amyloid plaques by inducting humoral immune response with Th2 skewed cytokine response in the Tg (APPswe, PS1dE9) Alzheimer's mouse model Therapeutic Agent(s):
Luteolin Isoorientin Rhamnosylisoorientin Derhamnosylmaysin
Maysin and its flavonoid derivative from centipedegrass attenuates amyloid plaques by inducting humoral immune response with Th2 skewed cytokine response in the Tg (APPswe, PS1dE9) Alzheimer's mouse model
Year:
2018 PI Name: Yuksel Melike PubMed/DOI:
29248542
Toluidine blue O modifies hippocampal amyloid pathology in a transgenic mouse model of Alzheimer's disease Therapeutic Agent(s):
Toluidine blue O modifies hippocampal amyloid pathology in a transgenic mouse model of Alzheimer's disease
